Nanobiotix
- Nanobiotix completed a sub-10% private placement by issuing new shares to US and EU institutional investors
- Proceeds will be used for the development of lead product NBTXR3 and preparation of its market access and launch
- Order book was of mainly long-only demand was covered by a majority of new institutional investors and institutional investors from the US